When the duty to warn runs to the prescriber, how the prescriber’s knowledge ends the case, and how federal preemption sits on top of it all

In the ordinary products case the manufacturer’s duty to warn runs to the user. Prescription drugs and medical devices are the great exception. There, the learned intermediary doctrine interposes the prescribing physician between manufacturer and patient: the manufacturer discharges its duty by adequately warning the physician, who—exercising independent medical judgment with knowledge of the individual patient—decides whether and how to prescribe and what to tell the patient. An adequate warning to the physician discharges the duty, and the manufacturer generally owes no duty to warn the patient directly. For anyone litigating a Missouri drug or device case, the doctrine reshapes both duty and causation, and it operates against a federal-preemption backdrop that can dispose of the claim before the doctrine is ever reached. The correct order of analysis, developed below, is preemption first, then the doctrine.

I. The Doctrine and Its Missouri Roots

Missouri adopted the doctrine early, at the Supreme Court, in Krug v. Sterling Drug, Inc., 416 S.W.2d 143 (Mo. 1967), a suit over permanent retinal damage from long-term use of an antimalarial. The Court framed the prescription-drug manufacturer’s obligation in language every later Missouri court quotes: the manufacturer has “a duty to properly warn the doctor of the dangers involved and it is incumbent upon the manufacturer to bring the warning home to the doctor,” 416 S.W.2d at 146. The leading modern restatement is Doe v. Alpha Therapeutic Corp., 3 S.W.3d 404 (Mo. App. E.D. 1999), brought by hemophiliac plaintiffs who contracted HIV from a Factor VIII blood concentrate. The Eastern District restated Krug and described the doctrine as “a corollary to the rule that a manufacturer of prescription drugs or products discharges its duty to warn by providing the physician with information about risks,” the physician acting “as a ‘learned intermediary’ between the manufacturer and the patient.”

The doctrine is not confined to pills. In Kirsch v. Picker International, Inc., 753 F.2d 670 (8th Cir. 1985), the Eighth Circuit, applying Missouri law, extended it to a medical device—radiation-therapy equipment—reasoning that such equipment “can be utilized only at the direction of a physician,” so “the manufacturer has a duty to properly warn only the doctor of the dangers associated with radiation therapy,” 753 F.2d at 670–71. Kirsch governs prescription and physician-administered devices generally, from radiation equipment to implanted hips and pelvic mesh; the early Court of Appeals decision Johnson v. Upjohn Co., 442 S.W.2d 93 (Mo. App. 1969), had already confirmed the drug rule shortly after Krug.

II. The Doctrine’s Real Teeth: Causation

The doctrine’s litigation power lies in causation, not duty. Even assuming an inadequate warning, the plaintiff must prove that an adequate warning to the prescribing physician would have changed the physician’s decision—that the physician would not have prescribed the drug or implanted the device, would have prescribed differently, or would have passed a different warning to a patient who then would have declined. Doe v. Alpha Therapeutic states the governing rule: a manufacturer’s failure to warn is “not the proximate cause of a patient’s injury if the prescribing physician had independent knowledge of the risk that the adequate warnings should have communicated.” Kirsch applied the identical logic to devices: “Picker’s failure to warn Dr. Murphy could not have been the proximate cause of Kirsch’s injury if Murphy was already aware of the cancer risks associated with radiation therapy.” The underlying causation standard is the “but for” test of Callahan v. Cardinal Glennon Hospital, 863 S.W.2d 852, 860 (Mo. banc 1993).

Two independent causation-breakers follow, and both make the prescriber’s deposition dispositive. First, independent knowledge: if the physician already knew the risk, the missing warning could not have caused anything (Kirsch; Doe v. Alpha). Second, would-have-prescribed-anyway: if the physician testifies she would have prescribed or implanted regardless of a stronger warning, causation fails as a matter of law. Missouri drug and device cases turn overwhelmingly on that deposition, which is why these claims are so often resolved on summary judgment. Defense counsel seeks testimony that the physician already knew the risk, read and found the existing label adequate, or would have proceeded regardless—any one of which ordinarily ends the warning claim. Plaintiff’s counsel must extract the converse, and must be prepared for the reality that most physicians resist testifying that a different label would have changed their clinical judgment.

III. The Exceptions and Missouri’s Cautious Posture

Other jurisdictions have carved exceptions to the doctrine. Missouri’s posture ranges from cautious to genuinely open.

Direct-to-consumer advertising—the headline issue. The national outlier is Perez v. Wyeth Laboratories Inc., 734 A.2d 1245 (N.J. 1999), where the New Jersey Supreme Court, in the Norplant context, held that “when mass marketing of prescription drugs seeks to influence a patient’s choice of a drug, a pharmaceutical manufacturer that makes direct claims to consumers . . . should not be unqualifiedly relieved of a duty to provide proper warnings,” reasoning that consumer-directed advertising “belies each of the premises” of the doctrine. Id. at 1247, 1257. New Jersey remains essentially alone. Missouri’s position must be stated precisely: Missouri has not adopted the direct-to-consumer exception, and it has not rejected it on the merits either. The only Missouri case squarely to present the argument, Doe v. Alpha Therapeutic, declined to reach it on preservation grounds—the plaintiffs failed to object to the pattern instructions or to request an exception instruction. The accurate statement is therefore that no Missouri appellate court has adopted a direct-to-consumer exception, and none has rejected it on the merits; its status is an open question—unlikely to be embraced given the national trend, but formally undecided.

Contraceptives—where Missouri actually has authority. The strongest exception footing in Missouri is the contraceptive context, because of Hill v. Searle Laboratories, 884 F.2d 1064 (8th Cir. 1989), applying Missouri law. The court declined to apply the learned intermediary rule to a physician-inserted copper IUD, reasoning that “birth control is a private and personal matter” and that with contraceptives the prescribing physician “do[es] not make an individualized medical judgment,” so the patient was entitled to a direct warning; the court reversed summary judgment and remanded. Id. at 1068–71. Hill is an Eighth Circuit prediction of Missouri law rather than a Missouri Supreme Court holding, so a state court is not bound by it—but it is real authority recognizing a contraceptive limit, and it should be presented as such.

Mass immunization and vaccines. The mass-immunization exception—recognized in Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968), and Reyes v. Wyeth Laboratories, 498 F.2d 1264 (5th Cir. 1974), where a biologic is dispensed en masse without individualized physician judgment—has no Missouri holding adopting or rejecting it and is best treated as open. For covered childhood vaccines, the analysis is largely displaced by the National Childhood Vaccine Injury Act, 42 U.S.C. §§ 300aa-1 et seq., which channels claims into the vaccine program, and Bruesewitz v. Wyeth LLC, 562 U.S. 223 (2011), which preempts state-law design-defect claims for covered vaccines; surviving warning claims remain subject to the learned intermediary doctrine.

IV. The Federal Preemption Overlay

Preemption is logically and practically antecedent to the doctrine: if the state-law warning or design claim is preempted, the court never reaches whether the warning to the physician was adequate. The applicable rule turns on drug versus device and, within drugs, brand versus generic.

Brand-name drugs—generally not preempted. Wyeth v. Levine, 555 U.S. 555 (2009), held a state failure-to-warn claim against a brand manufacturer not preempted, because the FDA’s “changes being effected” regulation lets a brand manufacturer strengthen a warning without prior approval, so compliance with both federal and state duties is not impossible; there is no preemption “[a]bsent clear evidence that the FDA would not have approved a change,” and “impossibility pre-emption is a demanding defense,” 555 U.S. at 571, 573. Merck Sharp & Dohme Corp. v. Albrecht, 587 U.S. 299 (2019), later held that whether “clear evidence” exists is a question of law for the judge. For brand drugs and devices, then, warning claims usually survive preemption and the learned intermediary doctrine does the real work.

Generic drugs—generally preempted. PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), held state failure-to-warn claims against generic manufacturers preempted, because a federal duty of “sameness” requires the generic label to match the brand, making it impossible to comply with a state duty to warn differently; and Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013), extended preemption to generic design-defect claims, rejecting the “stop-selling” rationale. After Mensing and Bartlett, most claims against generic manufacturers—warning and design—are preempted, and generic cases often die on preemption before the doctrine is reached.

Devices—preemption keyed to the FDA pathway. Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), held that the Medical Device Amendments’ express preemption clause bars common-law claims imposing requirements “different from, or in addition to” the federal requirements imposed through premarket approval (PMA) of a Class III device, while preserving “parallel” claims premised on a violation of FDA requirements, 552 U.S. at 330. Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996), held that a device cleared through the lighter section 510(k) “substantial equivalence” pathway is generally not expressly preempted, because 510(k) imposes no device-specific federal requirements. The practical consequence is significant for the Missouri device docket: because most pelvic-mesh and many orthopedic implants cleared via 510(k), those cases are largely not expressly preempted, which is exactly why they turn on Missouri learned-intermediary and warning-causation analysis rather than on Riegel. Sequence the analysis accordingly: ask first whether the claim is preempted (generic drug? PMA device?), and only then whether the doctrine defeats duty or causation.

V. Application to Medical Devices

Kirsch is the doorway, and the doctrine reaches any device usable only at a physician’s direction—implanted and physician-administered Class II and Class III devices alike. The distinction that matters is prescription-use versus over-the-counter: an OTC product carries a direct duty to warn the consumer, while a prescription or physician-directed device routes the duty through the implanting or prescribing physician, whose deposition becomes the causation battleground exactly as with a prescriber of drugs. Two cautions from the modern device docket bear noting. First, an appellate affirmance in a device case may rest on grounds other than the doctrine; in Bayes v. Biomet, Inc., 55 F.4th 643 (8th Cir. 2022), the Eighth Circuit’s published affirmance turned on negligent design and damages, and the learned intermediary analysis lives in the district-court failure-to-warn ruling rather than the appellate opinion—so cite the level that actually decided the point. Second, device plaintiffs face a second causation gate independent of warning causation: proving the defect-injury link through qualified expert testimony, as Redd v. DePuy Orthopaedics, Inc. illustrates, where a hip-implant claim failed on Daubert expert-causation grounds. The recent Missouri federal dockets—pelvic mesh and orthopedic implants across the Eastern and Western Districts—are where the doctrine is now most actively litigated; those unpublished decisions should be pulled and confirmed before they are cited.

VI. Litigation Strategy and Analytical Tensions

Defense. Move on preemption first—generic drug (Mensing/Bartlett) or PMA device (Riegel)—to dispose of the case before the doctrine. If the claim survives, deploy the doctrine on summary judgment through the prescriber deposition: establish independent knowledge (Kirsch; Doe v. Alpha) or would-have-prescribed-anyway testimony. Argue the warning was adequate as a matter of law where the specific risk appeared in the label or a black box, and resist any direct-to-consumer or mass-marketing theory by noting that no Missouri court has adopted an exception.

Plaintiff. Defeat preemption by pleading parallel claims (device) or targeting the brand manufacturer under Levine, stressing that “clear evidence” is a demanding, judge-decided burden (Albrecht). On the doctrine, attack the adequacy of the warning to the physician—content, prominence, timing—and build decision-altering causation through the prescriber, who was unaware of the specific risk and would have changed course. Where the facts fit, press the contraceptive limit (Hill) or the mass-immunization limit, and—unlike the plaintiffs in Doe v. Alpha—preserve a clean direct-to-consumer record with proper objections and a tendered instruction, so the merits question is actually teed up.

The tensions worth flagging are three. The direct-to-consumer exception’s undecided status is the doctrine’s soft spot: with modern pharmaceutical advertising ubiquitous, the Perez rationale is a live, unresolved argument in Missouri, and Doe v. Alpha ducked it. The preemption–doctrine interaction runs in opposite directions and must be sequenced: preemption can buttress the doctrine (killing generic and PMA-device claims outright) or leave it fully exposed (brand drugs, 510(k) devices), and misordering the analysis is a common briefing error. And adequacy-to-the-physician is a moving target—the presence of a black-box warning tends to win for defendants (Brinkley v. Pfizer, 772 F.3d 1133 (8th Cir. 2014), holding a Chantix warning adequate as a matter of law), while the omission of a specific mechanism or magnitude of risk keeps the question for the jury. Master the causation corollary and the preemption sequence, and the rest of the doctrine follows.

Related in the Products Liability Series

• Missouri Product Liability Law: The Complete Guide
• Design Defect Claims Under Missouri Law — the undefined “unreasonably dangerous” standard and how design cases are submitted.
• Manufacturing Defect Claims Under Missouri Law — proving departure from design by circumstantial inference and expert proof.
• Failure-to-Warn Claims Under Missouri Law — the two causation prongs and the read-and-heed presumption.
• Safer Alternative Design Requirements — why Missouri treats alternative design as evidence, not an element.
• Product Recall Evidence in Civil Litigation — the Pollard framework and the limits on recall admissibility.
• Investigating the Products Case: Preservation, Spoliation, and Cost.